FluoroPharma Medical, Inc. (FPMI) Announces Additional Patent Protection in the U.S. and China
Today before the opening bell, FluoroPharma Medical announced that composition of matter patents covering AZPET, the company's Alzheimer's Disease agent, have been issued by the U.S. patent office expiring in 2028. FluoroPharma has also been granted patent rights in China for BFPET, its imaging agent for measuring cardiovascular blood flow. The patents will expand the company’s intellectual property protection in these important growth markets where diagnostic imaging is playing an increasingly significant role in the early detection of disease. FluoroPharma is developing breakthrough diagnostic imaging products that utilize positron emission tomography (PET) technology, a molecular imaging platform that is growing…